COMP <GO>
ACAD vs PBLS // EV/EBITDA & P/E VALUATION
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Parabilis Medicines Inc. (NASDAQ) • 15-METRIC TALLY: ACAD 1
— PBLS 1
■ METRIC PARITY
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
valuation
31.2x
LAST: $28.70 (+1.88%) • MKT CAP: $3.50B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. PBLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | PBLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 31.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 9.80% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 36.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 48.5 | -2.97 | PBLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $3.50B | $77.0M | ACAD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | PBLS REV | ACAD GROSS % | PBLS GROSS % | ACAD FCF | PBLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $0 | 91.7% | — | $105.1M | — |
| FY 2024 | $957.8M | — | 91.5% | — | $157.2M | — |
| FY 2023 | $726.4M | — | — | — | $16.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
PBLS // BETA —